Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr78.10 SEK
Change Today +0.60 / 0.77%
Volume 326.3K
EKTAB On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
OTC US
Frankfurt
As of 8:50 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAB) Snapshot

Open
kr77.45
Previous Close
kr77.50
Day High
kr78.45
Day Low
kr77.45
52 Week High
05/16/14 - kr94.71
52 Week Low
10/16/14 - kr63.95
Market Cap
29.9B
Average Volume 10 Days
1.9M
EPS TTM
kr2.69
Shares Outstanding
368.6M
EX-Date
08/29/14
P/E TM
29.0x
Dividend
kr1.50
Dividend Yield
2.56%
Current Stock Chart for ELEKTA AB-B SHS (EKTAB)

Related News

No related news articles were found.

elekta ab-b shs (EKTAB) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAB) Details

Elekta AB (publ), develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend sytem for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualize tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,802 Employees
Last Reported Date: 03/4/15
Founded in 1972

elekta ab-b shs (EKTAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAB) Key Developments

Elekta AB Announces Åsa Hedin, Executive Vice President Corporate Strategy to Leave the Company March 30, 2015

Elekta announced that Åsa Hedin, Executive Vice President Corporate Strategy, has accepted a career opportunity outside of Elekta and will leave the Company March 30, 2015.

Elekta AB Reports Earnings Results for the First Nine Months of the Fiscal Year 2015; Provides Earnings Guidance for the Fiscal Year 2015

Elekta AB reported earnings results for the first nine months of the fiscal year 2015. For the quarter, net sales increased 4% to SEK 6,984 million compared to SEK 6,740 million in 2014, equivalent to a decrease of 3% based on constant exchange rates. EBITA amounted to SEK 705 million compared to SEK 895 million in 2014 before non-recurring items. Net income amounted to SEK 215 million compared to SEK 333 million in 2014. Earnings per share amounted to SEK 0.55 compared to SEK 0.87 in 2014 before dilution and SEK 0.55 compared to SEK 0.87 in 2014 after dilution. Cash flow after continuous investments amounted to negative SEK -541 million compared to negative SEK 550 in 2014. The company provided earnings guidance for the fiscal year 2015. Based on the current market conditions net sales are expected to grow 4% based on constant exchange rates. EBITA is expected to increase approximately 6% based on constant exchange rates. Cash flow after continuous investments is targeted to exceed SEK 1.1 billion, representing a cash conversion exceeding 60%.

Elekta Plans to Introduce MRI-Guided Radiation Therapy System in 2017

Elekta announced its latest research and development initiatives, with special focus on Atlantic, the first generation high field MRI-guided radiation therapy system. The company unveiled plans to introduce this game-changing technology in 2017 and deliver the first systems in 2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAB:SS kr78.10 SEK +0.60

EKTAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $9.30 USD +0.08
American Shared Hospital Services $2.50 USD -0.05
Eckert-Ziegler Bebig €1.30 EUR 0.00
MRI Interventions Inc $1.04 USD +0.0765
RaySearch Laboratories AB kr70.50 SEK +0.75
View Industry Companies
 

Industry Analysis

EKTAB

Industry Average

Valuation EKTAB Industry Range
Price/Earnings 28.0x
Price/Sales 2.6x
Price/Book 4.6x
Price/Cash Flow 26.8x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.